Trial record 1 of 1 for:    GC P#02.01.001
Previous Study | Return to List | Next Study

Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy (ExCell)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00469729
Recruitment Status : Completed
First Posted : May 4, 2007
Last Update Posted : July 10, 2015
Information provided by (Responsible Party):
Gamida Cell -Teva Joint Venture Ltd.

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : February 2013
  Actual Study Completion Date : June 2015
Shpall EJ, M.d.L., K. Chan, R. Champlin, A. Gee, P. Thall, K. Komanduri, D. Couriel, C. Hosing, B. Andersson, R. Jones, S. Giralt, S. Karandish, T. Sadeghi, B. Muriera, S. O'Connor, L. Wooten, X. Wang, S. Robinson, P. Fu, J. Wilson, T. Peled, F. Grynspan, A. Nagler, J. McMannis; A Phase I/II Study of Ex Vivo Expanded Cord Blood for Leukemia and Lymphoma. ISCT 2005 - conference publication, 2005.

Publications automatically indexed to this study by Identifier (NCT Number):